DrugDashboards

Dextromethorphan HBr. and Guaifenesin

Dextromethorphan HBr. and Guaifenesin · DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL; GUAIFENESIN 100 mg/5mL · Solution · Oral · Rising Pharma Holdings, Inc.

NDC 57237-0312-51 · 100 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE / 5 mL in 1 CUP, UNIT-DOSE · OTC MONOGRAPH DRUG · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4$0.6Dec 2024May 2025$0.4051
7 price points · per ML · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$207.95
Reported to Texas DSHS · 2025 annual filing · Rising Pharma Holdings, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$5,439
187 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for dextromethorphan hbr, guaifenesin (other) in the next 90 days

sole-source market · price up 2% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
M012.85
TE code
Approval date
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Dextromethorphan HBr. and Guaifenesin (Solution)

LabelerStrengthFirst seenLast seen
Everpharm LLCDEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL; GUAIFENESIN 100 mg/5mLJul 15, 2026Sep 2, 2026
Everpharm LLCDEXTROMETHORPHAN HYDROBROMIDE 20 mg/10mL; GUAIFENESIN 200 mg/10mLJul 15, 2026Sep 2, 2026
Rising Pharma Holdings, Inc.DEXTROMETHORPHAN HYDROBROMIDE 10 mg/5mL; GUAIFENESIN 100 mg/5mLJul 15, 2026Sep 2, 2026
Rising Pharma Holdings, Inc.DEXTROMETHORPHAN HYDROBROMIDE 20 mg/10mL; GUAIFENESIN 200 mg/10mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Dextromethorphan HBr. and Guaifenesin — NDC 57237-0312-51," retrieved September 3, 2026, https://drugdashboards.com/drug/57237031251.

Free to cite with attribution — see how the data is put together.